Brand Name
Sensipar
Generic Name
Cinacalcet
View Brand Information FDA approval date: April 04, 2004
Classification: Calcium-sensing Receptor Agonist
Form: Tablet
What is Sensipar (Cinacalcet)?
Sensipar is a positive modulator of the calcium sensing receptor indicated for: Secondary Hyperparathyroidism in adult patients with chronic kidney disease on dialysis.
Approved To Treat
Top Global Experts
Save this treatment for later
Not sure about your diagnosis?
Tired of the same old research?
Related Clinical Trials
A Multicenter, Randomized, Double-blind, Double-dummy, Phase III Study to Evaluate the Efficacy and Safety of MT1013 Versus Cinacalcet as Active Control in Secondary Hyperparathyroidism Patients on Maintenance Dialysis
Summary: MT1013 is a first-in-class dual-target agonist. This study is a multicenter, randomized, double-blind, double-dummy phase III clinical study being conducetd to evaluate the efficacy and safety of MT1013 compared with active control cinacalcet in secondary hyperparathyroidism patients on maintenance dialysis. Subjects will be 1:1 randomized to receive MT1013 or cinacalcet for 26 weeks. Evaluations ...